Compare CRSR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | DSGN |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.0M | 579.9M |
| IPO Year | 2020 | 2021 |
| Metric | CRSR | DSGN |
|---|---|---|
| Price | $6.31 | $12.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $8.50 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 999.4K | 262.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,480,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $4.48 | $3.11 |
| 52 Week High | $10.29 | $12.98 |
| Indicator | CRSR | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 61.33 |
| Support Level | $6.09 | $9.71 |
| Resistance Level | $6.94 | N/A |
| Average True Range (ATR) | 0.22 | 0.58 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 99.57 | 75.37 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.